Lex­i­con slams FDA over hear­ing de­nial fol­low­ing a CRL for its SGLT2 in­hibitor can­di­date

Lex­i­con Phar­ma­ceu­ti­cal is not giv­ing up on its Type I di­a­betes can­di­date, de­spite FDA’s re­peat­ed re­jec­tions. This week the com­pa­ny laid out its ar­gu­ment again …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER